{
    "nctId": "NCT00681122",
    "briefTitle": "CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)",
    "officialTitle": "An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 2600,
    "primaryOutcomeMeasure": "The compliance rate for the adjuvant AI medication will be analysed at one year based on the subject's assessment.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal woman with hormone sensitive early breast cancer\n* Documented decision of treatment with upfront adjuvant AI (either anastrozole or letrozole) according to current SmPC OR current treatment with AI (either anastrozole or letrozole) according to current SmPC, that has not exceeded thirteen weeks\n\nExclusion Criteria:\n\n* Upfront adjuvant AI medication which has exceeded thirteen weeks at randomisation\n* Concomitant adjuvant treatment with tamoxifen or exemestane\n* Previous use of adjuvant tamoxifen or exemestane exceeding thirteen weeks",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}